NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Jade Biosciences, Inc. (JBIO) Stock Analysis

Jade Biosciences, Inc. (JBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

JBIO

$15.13

+$0.27 (+1.82%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare JBIO with… →

JBIO Key Statistics

As of Oct 21, 2026
Trading
Open
$14.84
Previous Close
$14.86
Day's Range
14.72–15.43
52-Week Range
8.36–28.00
Volume
932.73K
Valuation
Market Cap
$962.23M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.92
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$127.41M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
63.60M
1-Year Return
+50.85%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
901.78K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, JBIO closed at $15.13, +50.85% over 1 year.

Jade Biosciences, Inc. (JBIO) has a market capitalization of $962.23M.

JBIO Stock Return by Calendar Year

Jade Biosciences, Inc. (JBIO) return since Jun 2021: what $10,000 became

1 year
$10,000 $15,085
+50.85%
5 years
$10,000 $341
−96.59%
Since Jun 2021
$10,000 $194
−98.06%

If you had invested $10,000 in Jade Biosciences, Inc. (JBIO) at the close on June 30, 2021, the earliest close on record here, it would have been worth $194 at the close on October 21, 2026: −98.06% in total, −52.40% a year, with dividends reinvested, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−1.94%
2025−82.93%
2024−88.29%
2023−22.76%
2022+148.52%
2021 (partial year)−48.36%

As of October 21, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Jade Biosciences, Inc. (JBIO) at $962.23M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 55 employees.

The most recent close on file for JBIO is $15.13, dated October 21, 2026. That is +$0.27 (+1.82%) against the previous close. Over the past 52 weeks the price has ranged from $8.36 to $28.00. The latest close sits 80.98% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $127.41M. Earnings per share on a trailing basis come to −1.92.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is +50.85%. Across 5 years the annualized return works out at −49.12%. Annualized volatility over the trailing 5 years is 98.23%.

Growth & Income

The dividend record for JBIO runs through 2025.

So far in 2026 the total return is −1.94%. Across the complete calendar years on file, 2022 returned +148.52% and 2024 returned −88.29%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Jade Biosciences, Inc. (JBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Jade Biosciences, Inc. JBIO $962.23M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Jade Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Visit website →